No Data
Bristol-Myers Squibb: Buy Rating Maintained Despite Opdualag Trial Setback, Strong Pipeline Expected to Drive Future Growth
Why Bristol-Myers Squibb (BMY) Is Among the Best Drug Stocks to Buy Now
New Five-Year Sotyktu (Deucravacitinib) Data Show Consistent Safety and Durable Response Rates in Moderate-to-Severe Plaque Psoriasis
Fund Update: AMERIPRISE FINANCIAL INC Just Disclosed New Holdings
Bristol-Myers Squibb's Melanoma Treatment Fails to Meet Primary Endpoint in Phase 3 Adjuvant Trial
Bristol-Myers Squibb: Disappointed in Outcome of RELATIVITY-098 Trial and That LAG-3 Inhibition in Adjuvant Setting Did Not Lead to Same Improved Efficacy Outcomes Seen in Advanced Melanoma >BMY
